Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730455 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
NCT02730455 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 277 participants.
The verdict
NCT02730455, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence, activities of daily living, neurologic function, quality of life, cognition, and safety and tolerability
Interventions
- DRUG Placebo
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-07-18 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730455
The ClinicalTrials.gov registry entry for NCT02730455 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02730455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730455 about?
NCT02730455 is a clinical study titled "Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke". The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical t...
What is the current status of trial NCT02730455?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2016-07-18. Estimated completion is 2017-11-20.
What interventions are being tested in trial NCT02730455?
The interventions under investigation include: Placebo (DRUG), natalizumab (DRUG).
Who is sponsoring clinical trial NCT02730455?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.